{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Intramuscular+Placebo&page=3", "query": { "intervention": "Matching Intramuscular Placebo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 111, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Intramuscular+Placebo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Intramuscular+Placebo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:51:02.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04305496", "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 818, "start_date": "2020-04-16", "completion_date": "2026-06-22", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305496" }, { "nct_id": "NCT02264288", "title": "Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Arterial Disease", "Diabetic Foot" ], "interventions": [ { "name": "PDA-002", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2014-10-23", "completion_date": "2018-02-27", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02264288" }, { "nct_id": "NCT05772156", "title": "Prophylactic Methylergonovine for Twin Cesarean", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Twin; Complicating Pregnancy", "Postpartum Hemorrhage" ], "interventions": [ { "name": "Methylergonovine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "FEMALE", "summary": "Up to 65 Years · Female only" }, "enrollment_count": 66, "start_date": "2023-03-07", "completion_date": "2024-03-11", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05772156" }, { "nct_id": "NCT02546960", "title": "A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ExPEC4V (4 : 4 : 4 : 4)", "type": "BIOLOGICAL" }, { "name": "ExPEC4V (4 : 4 : 4 : 8)", "type": "BIOLOGICAL" }, { "name": "ExPEC4V (8 : 8 : 8 : 8)", "type": "BIOLOGICAL" }, { "name": "ExPEC4V (8 : 8 : 8 : 16)", "type": "BIOLOGICAL" }, { "name": "ExPEC4V (16 : 16 : 16 : 16)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 848, "start_date": "2015-11-12", "completion_date": "2019-06-21", "has_results": false, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 17, "location_summary": "Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT02546960" }, { "nct_id": "NCT07513376", "title": "A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Intismeran", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab coformulated with berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 876, "start_date": "2026-05-04", "completion_date": "2038-05-11", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 23, "location_summary": "Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 19 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07513376" }, { "nct_id": "NCT04985760", "title": "Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Madhu Chhanda Choudhary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-09-30", "completion_date": "2026-01-16", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 2, "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985760" }, { "nct_id": "NCT05085366", "title": "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cytomegalovirus Infection" ], "interventions": [ { "name": "mRNA-1647", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "16 Years to 40 Years · Female only" }, "enrollment_count": 7454, "start_date": "2021-10-26", "completion_date": "2025-11-04", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 181, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 141 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05085366" }, { "nct_id": "NCT03500679", "title": "A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ExPEC4V", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-05-09", "completion_date": "2019-06-11", "has_results": true, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 2, "location_summary": "Wichita, Kansas • Knoxville, Tennessee", "locations": [ { "city": "Wichita", "state": "Kansas" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03500679" }, { "nct_id": "NCT00676715", "title": "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Avonex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 220, "start_date": "2008-07-17", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676715" }, { "nct_id": "NCT02076178", "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "744 Tablet", "type": "DRUG" }, { "name": "744 LA Injection", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "DRUG" }, { "name": "Placebo Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 127, "start_date": "2014-03-27", "completion_date": "2016-02-23", "has_results": true, "last_update_posted_date": "2017-12-15", "last_synced_at": "2026-10-14T02:51:02.805Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02076178" } ] }